Business
Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025
Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2025.
About this update from Quest Diagnostics Incorporated
[{"type":"list","items":[{"val":[{"type":"text","content":"First quarter revenues of $2.65 billion, up 12.1% from 2024","length":59,"tagName":"p"}]},{"val":[{"type":"text","content":"First quarter reported diluted earnings per share ("EPS") of $1.94, up 12.8% from 2024; and adjusted diluted EPS of $2.21, up 8.3% from 2024","length":150,"tagName":"p"}]},{"val":[{"type":"text","content":"Full year 2025 reported diluted EPS now expected to be between $8.62 and $8.87; and adjusted diluted EPS is expected to remain between $9.55 and $9.80","length":150,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":359,"olType":false},{"type":"text","content":"SECAUCUS, N.J., April 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2025.","length":223,"tagName":"p"},{"type":"image","alt":"Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)","displaySize":"","headline":null,"caption":"Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":190,"url":"https://media.zenfs.com/en/prnewswire.com/328ba769d21514205fa2226e0dacf99b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/10t_J0fsHk4Z61kiPTCtrg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMzNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/328ba769d21514205fa2226e0dacf99b","width":400,"height":190}},"href":"https://mma.prnewswire.com/media/200883/quest_diagnostics_incorporated_logo_logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""In the first quarter, we delivered strong revenue growth of approximately 12%, including nearly 2.5% in organic growth, as demand rebounded in March following weather impacts early in the quarter. Our growth was due to contributions from acquisitions and large enterprise accounts, demand for our advanced diagnostics portfolio, and expanded health plan access," said Jim Davis, Chairman, CEO and President. "We are reaffirming our revenue and adjusted EPS guidance for the full year 2025."","length":511,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"1","rowspan":"1","style":"PADDING-RIGHT:0.83em;PADDING-LEFT:0.17em;VERTICAL-AL...